• Nexstim received an order on Nov. 11, 2026, from a major U.S. medical center for an NBS 6 system.
• The system includes FDA-cleared motor mapping, speech mapping and therapy modules.
• The new customer plans to use the system for brain mapping in adult and pediatric patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexstim Oyj published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.